Drugs / SAL0133
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT07030504 | Jan 2023 → Jun 2025 overdue | — | Shenzhen Salubris Pharmaceuticals Co., Ltd. | Active not recruiting | No outcome recorded |
News releases announcing trial results or a regulatory action · 1
| Date | Issuer | Release |
|---|---|---|
| 2023-01-03 | Shenzhen Salubris Pharmaceuticals Co., Ltd. | Regulatory 用于治疗成人轻型/普通型新型冠状病毒肺炎的SAL0133片临床试验申请获受理 salubris.com ↗
近日，信立泰宣布， 其自主研发的创新小分子药物 SAL0133 片临床试验申请 已获得国家药品监督管理局受理。 |
All press releases naming this drug 1 release
| Date | Issuer | Release |
|---|---|---|
| 2023-01-03 | Shenzhen Salubris Pharmaceuticals Co., Ltd. | 用于治疗成人轻型/普通型新型冠状病毒肺炎的SAL0133片临床试验申请获受理 salubris.com ↗ |
Evidence & citations 1 cited value
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | SAL0133 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07030504 ↗ |